drugset / Trial / NCT04887792
Acetazolamide for Treatment Resistant Schizophrenia
Phase 1/2
Recruiting
60 enrolled
Vishwajit Nimgaonkar, MD PhD
Stanley Medical Research Institute · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
Timeline
- Start
- 2022-02-01
- Primary completion
- 2027-12-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Acetazolamide | Small molecule | 2 g | — |